BioSpace News Archive

The global reproductive genetics market size is expected to reach USD 11.23 Billion at a steady CAGR of 12.3% in 2028,.

Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced the appointment of Michael Elliott, MBBS, PhD, FRACP, as scientific advisor.

Rising preference for opioid therapy for management of post-operative pain and chronic pain, increasing use of oxycodone to relieve pain and suffering, and growing incidence of chronic pain across the globe are some key factors expected to drive market growth.

Increasing pharmaceutical spending, rising incidence of adverse drug reactions, and growing inclination towards outsourcing pharmacovigilance are key factors fueling global market growth.

Lyell Immunopharma, Inc. announced that Dr. Rick Klausner is resuming his role as Chair of Lyell’s Board of Directors following the end of a temporary medical leave which was disclosed by the Company on September 30, 2021.

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the grant of inducement awards to five new employees.

Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) today announced the selection of PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on intervention of the Interleukin-23 (IL-23) pathway, under the Company’s collaboration with Janssen Biotech, Inc. (Janssen).

CooperCompanies announced financial results for its fiscal fourth quarter and full year ended October 31, 2021.

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) today announced that Ken d’Entremont, Chief Executive Officer of Medexus, and Marcel Konrad, Chief Financial Officer of Medexus, will be participating in two upcoming virtual investor conferences.

IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), today announced that interim data from the ICE3 Clinical Trial on cryoablation of small, low-risk breast cancer was featured by Co-Primary Investigator, Dr. Kenneth Tomkovich at the Radiologists Society of North America (RSNA).